Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
LGC Clinical Diagnostics

QUIDEL

Develops, manufactures and markets rapid diagnostic tests at the point-ofcare (POC) that focus on infectious diseases... read more Featured Products: More products

Download Mobile App




Remote Dispensing of Emergency Release Red Blood Cells Assessed

By LabMedica International staff writers
Posted on 26 Oct 2022

Good transfusion practice requires meticulous attention to the correct identification of blood samples and the performance of pre-transfusion compatibility testing using validated procedures. More...

Patients with acute bleeding are frequently transfused with emergency release (ER) group O red blood cells (RBCs).

There are several different approaches to address this need, but most employ the provision of group O RBCs to avoid ABO incompatibility. First, the RBCs can be packed into a container for urgent transportation to the intended site of transfusion, which is typically an emergency department (ED) or trauma bay.

Medical Transfusion Specialists at the Alpert Medical School of Brown University (Providence, RI, USA) examined records of patients who received ER RBCs over a 30-month period. In total, 935 patients received ER RBCs over this 30-month period, 816 at hospital A and 119 at hospital B; 527 (56%) were trauma patients, and 408 (44%) were non-trauma patients. Nurses accessing the refrigerator were required to give patient identification information, when known, prior to removal of the ER RBCs, allowing technologists the opportunity to check for previous serologic records and communicate directly with the ED if a serologic incompatibility was potentially present.

ABO typing, antibody screening, antibody panels, and antiglobulin cross-matches were routinely performed using a gel column agglutination technique on automated blood bank analyzers (Ortho Vision; Ortho Clinical Diagnostics, Raritan, NJ, USA) using reagents from the vendor. Ficin gel panels were used where required to clarify antibody identification. Phenotyping was performed using a tube technique (Bio-Rad, Hercules, CA, USA).

The team reported that total of 2,055 RBCs were removed from the electronically connected satellite refrigerator (ECSR): 1,855 from hospital A and 200 from hospital B, 1,847 of which were transfused, yielding an average of 2.0 units transfused per patient. Thirty (3.4%) patients had a serologic abnormality, and most patients with antibodies were female (18/30 or 60%). As expected, most of the antibodies with known specificity were Rhesus or Kell antibodies (35/43, 81%). In 15 cases, incompatible RBCs were interdicted. In six cases, the transfusion was considered urgent, and an acute hemolytic transfusion reaction (AHR) occurred in four of these six (overall 0.4%), including one fatal AHR due to anti-KEL1.

The authors concluded that their data was indicative of slightly higher rates of AHR than previously reported, which is possibly related to the inclusion of a large number of non-trauma patients, and the prospective active evaluation of recipients of incompatible RBCs. Given the frequency of anti-K, they believe a policy of storing only KEL1-negative RBCs in ED refrigerators and that the use of ECSRs in emergency departments with a high volume of ER RBCs are useful steps to mitigate the risk inherent in the practice of ER RBC transfusion. The study was published in the October 2022 issue of the American Journal of Clinical Pathology.

Related Links:
Alpert Medical School of Brown University 
Ortho Clinical Diagnostics 
Bio-Rad 


Platinum Member
ADAMTS-13 Protease Activity Test
ATS-13 Activity Assay
Verification Panels for Assay Development & QC
Seroconversion Panels
Anti-Cyclic Citrullinated Peptide Test
GPP-100 Anti-CCP Kit
Gold Member
ESR Analyzer
miniiSED™
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: QIP-MS could predict and detect myeloma relapse earlier compared to currently used techniques (Photo courtesy of Adobe Stock)

Mass Spectrometry-Based Monitoring Technique to Predict and Identify Early Myeloma Relapse

Myeloma, a type of cancer that affects the bone marrow, is currently incurable, though many patients can live for over 10 years after diagnosis. However, around 1 in 5 individuals with myeloma have a high-risk... Read more

Immunology

view channel
Image: The cancer stem cell test can accurately choose more effective treatments (Photo courtesy of University of Cincinnati)

Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer

Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more

Technology

view channel
Image: Ziyang Wang and Shengxi Huang have developed a tool that enables precise insights into viral proteins and brain disease markers (Photo courtesy of Jeff Fitlow/Rice University)

Light Signature Algorithm to Enable Faster and More Precise Medical Diagnoses

Every material or molecule interacts with light in a unique way, creating a distinct pattern, much like a fingerprint. Optical spectroscopy, which involves shining a laser on a material and observing how... Read more

Industry

view channel
Image: The collaboration aims to leverage Oxford Nanopore\'s sequencing platform and Cepheid\'s GeneXpert system to advance the field of sequencing for infectious diseases (Photo courtesy of Cepheid)

Cepheid and Oxford Nanopore Technologies Partner on Advancing Automated Sequencing-Based Solutions

Cepheid (Sunnyvale, CA, USA), a leading molecular diagnostics company, and Oxford Nanopore Technologies (Oxford, UK), the company behind a new generation of sequencing-based molecular analysis technologies,... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.